Next Chapter for Weight Control — Small-Molecule GLP-1 Receptor Agonists?

  • Abel, Dale E. M.B., B.S., D.Phil.

  • From the Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles.

Disclosure forms provided by the author are available with the full text of this editorial at NEJM.org.

New England Journal of Medicine 389(10):p 949-950, September 7, 2023. | DOI: 10.1056/NEJMe2307285

Obesity is a major risk factor for many health conditions, including cardiovascular disease, type 2 diabetes, sleep apnea, and cancer. The therapeutic armamentarium for long-term weight management is limited by side effects and contraindications.1 Two injectable incretin-based glucagon-like peptide-1 (GLP-1) receptor agonists — liraglutide (3.0 mg daily) and semaglutide (2.4 mg weekly) — have been approved by the Food and Drug Administration (FDA) for weight management, with better side-effect profiles than other treatments. An oral formulation of semaglutide (7 or 14 mg once daily) has been approved by the FDA for the treatment of type 2 diabetes but not yet …

Corresponding Article

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

  • Wharton, Sean M.D.
  • Blevins, Thomas M.D.
  • Connery, Lisa M.D.
  • Rosenstock, Julio M.D.
  • Raha, Sohini Ph.D.
  • Liu, Rong Ph.D.
  • Ma, Xiaosu Ph.D.
  • Mather, Kieren J. M.D.
  • Haupt, Axel M.D.
  • Robins, Deborah M.S.
  • Pratt, Edward M.D.
  • Kazda, Christof M.D.
  • Konig, Manige M.D., Ph.D.
New England Journal of Medicine 389(10):p 877-888, September 7, 2023. | DOI: 10.1056/NEJMoa2302392
Copyright © 2023 Massachusetts Medical Society. All rights reserved.